Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas

BACKGROUND: ERBB-2 is overexpressed in about 20% of breast cancers (BCs), indicating poor prognosis. The receptor activator of nuclear factor-κB (RANK) pathway is implicated in ERBB-2 (+) BC. The purpose of this study was to elucidate the underlying molecular mechanism of this interaction and the be...

Descripción completa

Detalles Bibliográficos
Autores principales: Zoi, Ilianna, Karamouzis, Michalis V., Xingi, Evangelia, Sarantis, Panagiotis, Thomaidou, Dimitra, Lembessis, Panayiotis, Theocharis, Stamatios, Papavassiliou, Athanasios G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892243/
https://www.ncbi.nlm.nih.gov/pubmed/31796128
http://dx.doi.org/10.1186/s13058-019-1226-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892243/
https://www.ncbi.nlm.nih.gov/pubmed/31796128
http://dx.doi.org/10.1186/s13058-019-1226-9

Ejemplares similares